LSD May Receive US Approval for Anxiety Treatment by 2027

A late‑stage clinical trial has shown that the psychedelic drug LSD can significantly reduce symptoms of anxiety, according to data released by the study’s sponsor. The randomized, double‑blind study enrolled several hundred participants with generalized anxiety disorder and reported a marked improvement in anxiety scores after a single low‑dose administration, with benefits lasting several weeks. The results were presented at a major psychiatric conference and have prompted the sponsor to file a new drug application with the U.S. Food and Drug Administration.

The trial’s findings align with a growing body of research suggesting that psychedelics, when administered in controlled settings, can produce rapid and sustained therapeutic effects for mental health conditions that are often resistant to conventional treatments. Regulatory experts note that the data meet the FDA’s criteria for breakthrough therapy designation, which could expedite the review process. If the agency grants approval, the drug would become one of the first psychedelics to receive formal market authorization in the United States.

Industry observers anticipate that, pending a positive regulatory decision, the drug could reach U.S. patients within the next two years. The approval would mark a significant shift in the treatment landscape for anxiety disorders and could pave the way for further investigations into psychedelic medicines for other psychiatric conditions.